-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 29, Zhejiang Conba Pharmaceutical Co.
, Ltd.
issued an announcement stating that it would publicly transfer 25% of the shares of Deer Pharmaceuticals
.
, Ltd.
issued an announcement stating that it would publicly transfer 25% of the shares of Deer Pharmaceuticals
.
The content of the announcement shows: In order to focus on the development of the company's core business of the Chinese medicine health industry, timely disposal of inefficient assets and withdrawal of funds, Zhejiang Jinhua Kangenbei Biopharmaceutical Co.
, Ltd.
(hereinafter referred to as "Jinhua Kangenbei"), a subsidiary of Conba Holdings It is planned to transfer the 25% equity of Zhejiang Dier Pharmaceutical Co.
, Ltd.
(hereinafter referred to as "Dier Pharmaceutical") held by the Zhejiang Equity Exchange through public listing
.
, Ltd.
(hereinafter referred to as "Jinhua Kangenbei"), a subsidiary of Conba Holdings It is planned to transfer the 25% equity of Zhejiang Dier Pharmaceutical Co.
, Ltd.
(hereinafter referred to as "Dier Pharmaceutical") held by the Zhejiang Equity Exchange through public listing
.
According to the assessment, the assessed value of Jinhua Kangenbei's 25% equity stake in Dier Pharmaceutical is RMB 39,747,228.
58
.
The board of directors of Kang Enbei approved the transfer of these shares of Deer Pharmaceuticals at a listed price of not less than RMB 39,747,229
.
58
.
The board of directors of Kang Enbei approved the transfer of these shares of Deer Pharmaceuticals at a listed price of not less than RMB 39,747,229
.
The 25% equity of Dear Pharmaceuticals was acquired by Jinhua Kangenbei in April 2015 with a capital investment of RMB 27.
5 million.
However, in view of the fact that Dear Pharmaceuticals has not launched any new competitive products in recent years, the competitiveness of existing products has gradually increased.
Decrease, its main product, Xie Duan Zhuanggu Capsule, has not been included in the medical insurance, and there are greater uncertainties in the future business development.
Jinhua Kang Enbei intends to dispose of the equity held by Deer Pharmaceuticals
.
At present, the major shareholder of Dear Pharmaceuticals is Hainan Asia Pharmaceutical Co.
, Ltd.
, accounting for 52.
73%; other shareholders include: Zhang Yonggao, accounting for 16.
34%, and the other 6 natural-person shareholders accounting for 5.
93%
.
5 million.
However, in view of the fact that Dear Pharmaceuticals has not launched any new competitive products in recent years, the competitiveness of existing products has gradually increased.
Decrease, its main product, Xie Duan Zhuanggu Capsule, has not been included in the medical insurance, and there are greater uncertainties in the future business development.
Jinhua Kang Enbei intends to dispose of the equity held by Deer Pharmaceuticals
.
At present, the major shareholder of Dear Pharmaceuticals is Hainan Asia Pharmaceutical Co.
, Ltd.
, accounting for 52.
73%; other shareholders include: Zhang Yonggao, accounting for 16.
34%, and the other 6 natural-person shareholders accounting for 5.
93%
.
Speed up the mobilization of funds, Conba "continuous action"
Recently, Conba has been busy selling equity and assets.
In order to release equity pledges, repay debts, and develop products, Conba has transferred the equity of 4 holding companies in the past six months
.
In order to release equity pledges, repay debts, and develop products, Conba has transferred the equity of 4 holding companies in the past six months
.
On June 12, Zhejiang Conba Pharmaceutical Co.
, Ltd.
intends to transfer the 30% equity of Lanxi City Lanxin Small Loan Co.
, Ltd.
through the Zhejiang Equity Exchange.
The transfer will eventually cost 53.
37 million yuan.
The transfer was completed, and the industrial and commercial change registration and filing procedures were completed on October 28
.
, Ltd.
intends to transfer the 30% equity of Lanxi City Lanxin Small Loan Co.
, Ltd.
through the Zhejiang Equity Exchange.
The transfer will eventually cost 53.
37 million yuan.
The transfer was completed, and the industrial and commercial change registration and filing procedures were completed on October 28
.
On August 13, Zhejiang Conba Pharmaceutical Co.
, Ltd.
issued an announcement stating that the board of directors agreed that the company would transfer 100% equity of Guizhou Beite Pharmaceutical Co.
, Ltd.
through public listing in Zhejiang Equity Exchange; on November 6 it issued a supplementary announcement saying that it was the first time At the expiration of the listing period, no interested transferee of equity has been solicited
.
, Ltd.
issued an announcement stating that the board of directors agreed that the company would transfer 100% equity of Guizhou Beite Pharmaceutical Co.
, Ltd.
through public listing in Zhejiang Equity Exchange; on November 6 it issued a supplementary announcement saying that it was the first time At the expiration of the listing period, no interested transferee of equity has been solicited
.
On September 23, Zhejiang Conba Pharmaceutical Co.
, Ltd.
intends to transfer its 42% equity in Jiangxi Zhenshiming Pharmaceutical Co.
, Ltd.
through public listing in Zhejiang Property Rights Exchange, at a listed reserve price of not less than 1,680,000,000 yuan.
No new progress has been announced yet
.
, Ltd.
intends to transfer its 42% equity in Jiangxi Zhenshiming Pharmaceutical Co.
, Ltd.
through public listing in Zhejiang Property Rights Exchange, at a listed reserve price of not less than 1,680,000,000 yuan.
No new progress has been announced yet
.
In addition to the transfer of equity, Conba has also recently released a number of pledges and returned the funds raised.
The company's core managers and shareholders have also announced the shareholding increase plan.
It seems that the move to revitalize the funds has achieved obvious results
.
The company's core managers and shareholders have also announced the shareholding increase plan.
It seems that the move to revitalize the funds has achieved obvious results
.
Many pharmaceutical companies "sell and sell"
At the end of the year, many pharmaceutical companies sold their assets and transferred shares one after another in order to make their annual reports more "beautiful"
.
.
On the evening of November 19, Renfu Medicine issued an announcement stating that it had signed a "Share Transfer Agreement" with Anda North America on November 19, 2021, and planned to transfer approximately 2.
52% of the company's shares of Huatai Insurance to it at a transfer price of RMB About 1.
026 billion yuan
.
52% of the company's shares of Huatai Insurance to it at a transfer price of RMB About 1.
026 billion yuan
.
On the evening of November 15, Laimei Pharmaceutical announced that Chengdu Yaoyun Pharmaceutical Technology Co.
, Ltd.
planned to increase the capital of Chengdu Jinxing Health Pharmaceutical Co.
, Ltd.
, a subsidiary of the listed company, by 113 million yuan
.
After the transaction is completed, Yaoyun Pharmaceutical will hold 61% of the equity of Jinxing Pharmaceutical
.
Upon completion of the transaction, Laimei Pharmaceutical's shareholding in Jinxing Pharmaceutical will drop from 90% to 35.
1%, and Jinxing Pharmaceutical will no longer be included in Laimei Pharmaceutical's consolidated statements
.
, Ltd.
planned to increase the capital of Chengdu Jinxing Health Pharmaceutical Co.
, Ltd.
, a subsidiary of the listed company, by 113 million yuan
.
After the transaction is completed, Yaoyun Pharmaceutical will hold 61% of the equity of Jinxing Pharmaceutical
.
Upon completion of the transaction, Laimei Pharmaceutical's shareholding in Jinxing Pharmaceutical will drop from 90% to 35.
1%, and Jinxing Pharmaceutical will no longer be included in Laimei Pharmaceutical's consolidated statements
.
On the evening of November 11, Dongyang Sunshine issued an announcement stating that the company intends to transfer the company’s total 452 million shares of Dongyang Sunshine to Guangdong Dongyang Sunshine Pharmaceutical Co.
, Ltd.
and its wholly-owned subsidiary, Hong Kong Dongyang Sunshine Sales Co.
, Ltd.
, accounting for approximately Dongyang Sunshine.
51.
41% of Sunshine Pharmaceutical’s total equity, with a transaction price of 3.
723 billion yuan
.
, Ltd.
and its wholly-owned subsidiary, Hong Kong Dongyang Sunshine Sales Co.
, Ltd.
, accounting for approximately Dongyang Sunshine.
51.
41% of Sunshine Pharmaceutical’s total equity, with a transaction price of 3.
723 billion yuan
.
On November 4, Jinghua Pharmaceutical issued an announcement stating that it had recently completed the sale of equity in its subsidiary Wannianchang Pharmaceutical
.
Upon notification from Nantong Public Resources Trading Center, the transferee of the equity is Jiangsu Qichen New Materials Co.
, Ltd.
, with a transaction amount of RMB 69,398,739.
00
.
.
Upon notification from Nantong Public Resources Trading Center, the transferee of the equity is Jiangsu Qichen New Materials Co.
, Ltd.
, with a transaction amount of RMB 69,398,739.
00
.
The sale of non-core business, the transfer of unprofitable subsidiaries for corporate sustainable development is favorable; revitalize the capital, to resolve the current difficulties, focus on core product R & D investment, the national pharmaceutical industry wants to focus, healthy development objectives
.
.
On November 29, Zhejiang Conba Pharmaceutical Co.
, Ltd.
issued an announcement stating that it would publicly transfer 25% of the shares of Deer Pharmaceuticals
.
, Ltd.
issued an announcement stating that it would publicly transfer 25% of the shares of Deer Pharmaceuticals
.
The content of the announcement shows: In order to focus on the development of the company's core business of the Chinese medicine health industry, timely disposal of inefficient assets and withdrawal of funds, Zhejiang Jinhua Kangenbei Biopharmaceutical Co.
, Ltd.
(hereinafter referred to as "Jinhua Kangenbei"), a subsidiary of Conba Holdings It is planned to transfer the 25% equity of Zhejiang Dier Pharmaceutical Co.
, Ltd.
(hereinafter referred to as "Dier Pharmaceutical") held by the Zhejiang Equity Exchange through public listing
.
, Ltd.
(hereinafter referred to as "Jinhua Kangenbei"), a subsidiary of Conba Holdings It is planned to transfer the 25% equity of Zhejiang Dier Pharmaceutical Co.
, Ltd.
(hereinafter referred to as "Dier Pharmaceutical") held by the Zhejiang Equity Exchange through public listing
.
According to the assessment, the assessed value of Jinhua Kangenbei's 25% equity stake in Dier Pharmaceutical is RMB 39,747,228.
58
.
The board of directors of Kang Enbei approved the transfer of these shares of Deer Pharmaceuticals at a listed price of not less than RMB 39,747,229
.
58
.
The board of directors of Kang Enbei approved the transfer of these shares of Deer Pharmaceuticals at a listed price of not less than RMB 39,747,229
.
The 25% equity of Dear Pharmaceuticals was acquired by Jinhua Kangenbei in April 2015 with a capital investment of RMB 27.
5 million.
However, in view of the fact that Dear Pharmaceuticals has not launched any new competitive products in recent years, the competitiveness of existing products has gradually increased.
Decrease, its main product, Xie Duan Zhuanggu Capsule, has not been included in the medical insurance, and there are greater uncertainties in the future business development.
Jinhua Kang Enbei intends to dispose of the equity held by Deer Pharmaceuticals
.
At present, the major shareholder of Dear Pharmaceuticals is Hainan Asia Pharmaceutical Co.
, Ltd.
, accounting for 52.
73%; other shareholders include: Zhang Yonggao, accounting for 16.
34%, and the other 6 natural-person shareholders accounting for 5.
93%
.
5 million.
However, in view of the fact that Dear Pharmaceuticals has not launched any new competitive products in recent years, the competitiveness of existing products has gradually increased.
Decrease, its main product, Xie Duan Zhuanggu Capsule, has not been included in the medical insurance, and there are greater uncertainties in the future business development.
Jinhua Kang Enbei intends to dispose of the equity held by Deer Pharmaceuticals
.
At present, the major shareholder of Dear Pharmaceuticals is Hainan Asia Pharmaceutical Co.
, Ltd.
, accounting for 52.
73%; other shareholders include: Zhang Yonggao, accounting for 16.
34%, and the other 6 natural-person shareholders accounting for 5.
93%
.
Speed up the mobilization of funds, Conba "continuous action"
Recently, Conba has been busy selling equity and assets.
In order to release equity pledges, repay debts, and develop products, Conba has transferred the equity of 4 holding companies in the past six months
.
In order to release equity pledges, repay debts, and develop products, Conba has transferred the equity of 4 holding companies in the past six months
.
On June 12, Zhejiang Conba Pharmaceutical Co.
, Ltd.
intends to transfer the 30% equity of Lanxi City Lanxin Small Loan Co.
, Ltd.
through the Zhejiang Equity Exchange.
The transfer will eventually cost 53.
37 million yuan.
The transfer was completed, and the industrial and commercial change registration and filing procedures were completed on October 28
.
, Ltd.
intends to transfer the 30% equity of Lanxi City Lanxin Small Loan Co.
, Ltd.
through the Zhejiang Equity Exchange.
The transfer will eventually cost 53.
37 million yuan.
The transfer was completed, and the industrial and commercial change registration and filing procedures were completed on October 28
.
On August 13, Zhejiang Conba Pharmaceutical Co.
, Ltd.
issued an announcement stating that the board of directors agreed that the company would transfer 100% equity of Guizhou Beite Pharmaceutical Co.
, Ltd.
through public listing in Zhejiang Equity Exchange; on November 6 it issued a supplementary announcement saying that it was the first time At the expiration of the listing period, no interested transferee of equity has been solicited
.
, Ltd.
issued an announcement stating that the board of directors agreed that the company would transfer 100% equity of Guizhou Beite Pharmaceutical Co.
, Ltd.
through public listing in Zhejiang Equity Exchange; on November 6 it issued a supplementary announcement saying that it was the first time At the expiration of the listing period, no interested transferee of equity has been solicited
.
On September 23, Zhejiang Conba Pharmaceutical Co.
, Ltd.
intends to transfer its 42% equity in Jiangxi Zhenshiming Pharmaceutical Co.
, Ltd.
through public listing in Zhejiang Property Rights Exchange, at a listed reserve price of not less than 1,680,000,000 yuan.
No new progress has been announced yet
.
, Ltd.
intends to transfer its 42% equity in Jiangxi Zhenshiming Pharmaceutical Co.
, Ltd.
through public listing in Zhejiang Property Rights Exchange, at a listed reserve price of not less than 1,680,000,000 yuan.
No new progress has been announced yet
.
In addition to the transfer of equity, Conba has also recently released a number of pledges and returned the funds raised.
The company's core managers and shareholders have also announced the shareholding increase plan.
It seems that the move to revitalize the funds has achieved obvious results
.
The company's core managers and shareholders have also announced the shareholding increase plan.
It seems that the move to revitalize the funds has achieved obvious results
.
Many pharmaceutical companies "sell and sell"
At the end of the year, many pharmaceutical companies sold their assets and transferred shares one after another in order to make their annual reports more "beautiful"
.
.
On the evening of November 19, Renfu Medicine issued an announcement stating that it had signed a "Share Transfer Agreement" with Anda North America on November 19, 2021, and planned to transfer approximately 2.
52% of the company's shares of Huatai Insurance to it at a transfer price of RMB About 1.
026 billion yuan
.
52% of the company's shares of Huatai Insurance to it at a transfer price of RMB About 1.
026 billion yuan
.
On the evening of November 15, Laimei Pharmaceutical announced that Chengdu Yaoyun Pharmaceutical Technology Co.
, Ltd.
planned to increase the capital of Chengdu Jinxing Health Pharmaceutical Co.
, Ltd.
, a subsidiary of the listed company, by 113 million yuan
.
After the transaction is completed, Yaoyun Pharmaceutical will hold 61% of the equity of Jinxing Pharmaceutical
.
Upon completion of the transaction, Laimei Pharmaceutical's shareholding in Jinxing Pharmaceutical will drop from 90% to 35.
1%, and Jinxing Pharmaceutical will no longer be included in Laimei Pharmaceutical's consolidated statements
.
, Ltd.
planned to increase the capital of Chengdu Jinxing Health Pharmaceutical Co.
, Ltd.
, a subsidiary of the listed company, by 113 million yuan
.
After the transaction is completed, Yaoyun Pharmaceutical will hold 61% of the equity of Jinxing Pharmaceutical
.
Upon completion of the transaction, Laimei Pharmaceutical's shareholding in Jinxing Pharmaceutical will drop from 90% to 35.
1%, and Jinxing Pharmaceutical will no longer be included in Laimei Pharmaceutical's consolidated statements
.
On the evening of November 11, Dongyang Sunshine issued an announcement stating that the company intends to transfer the company’s total 452 million shares of Dongyang Sunshine to Guangdong Dongyang Sunshine Pharmaceutical Co.
, Ltd.
and its wholly-owned subsidiary, Hong Kong Dongyang Sunshine Sales Co.
, Ltd.
, accounting for approximately Dongyang Sunshine.
51.
41% of Sunshine Pharmaceutical’s total equity, with a transaction price of 3.
723 billion yuan
.
, Ltd.
and its wholly-owned subsidiary, Hong Kong Dongyang Sunshine Sales Co.
, Ltd.
, accounting for approximately Dongyang Sunshine.
51.
41% of Sunshine Pharmaceutical’s total equity, with a transaction price of 3.
723 billion yuan
.
On November 4, Jinghua Pharmaceutical issued an announcement stating that it had recently completed the sale of equity in its subsidiary Wannianchang Pharmaceutical
.
Upon notification from Nantong Public Resources Trading Center, the transferee of the equity is Jiangsu Qichen New Materials Co.
, Ltd.
, with a transaction amount of RMB 69,398,739.
00
.
.
Upon notification from Nantong Public Resources Trading Center, the transferee of the equity is Jiangsu Qichen New Materials Co.
, Ltd.
, with a transaction amount of RMB 69,398,739.
00
.
The sale of non-core business, the transfer of unprofitable subsidiaries for corporate sustainable development is favorable; revitalize the capital, to resolve the current difficulties, focus on core product R & D investment, the national pharmaceutical industry wants to focus, healthy development objectives
.
.
On November 29, Zhejiang Conba Pharmaceutical Co.
, Ltd.
issued an announcement stating that it would publicly transfer 25% of the shares of Deer Pharmaceuticals
.
, Ltd.
issued an announcement stating that it would publicly transfer 25% of the shares of Deer Pharmaceuticals
.
The content of the announcement shows: In order to focus on the development of the company's core business of the Chinese medicine health industry, timely disposal of inefficient assets and withdrawal of funds, Zhejiang Jinhua Kangenbei Biopharmaceutical Co.
, Ltd.
(hereinafter referred to as "Jinhua Kangenbei"), a subsidiary of Conba Holdings It is planned to transfer the 25% equity of Zhejiang Dier Pharmaceutical Co.
, Ltd.
(hereinafter referred to as "Dier Pharmaceutical") held by the Zhejiang Equity Exchange through public listing
.
, Ltd.
(hereinafter referred to as "Jinhua Kangenbei"), a subsidiary of Conba Holdings It is planned to transfer the 25% equity of Zhejiang Dier Pharmaceutical Co.
, Ltd.
(hereinafter referred to as "Dier Pharmaceutical") held by the Zhejiang Equity Exchange through public listing
.
According to the assessment, the assessed value of Jinhua Kangenbei's 25% equity stake in Dier Pharmaceutical is RMB 39,747,228.
58
.
The board of directors of Kang Enbei approved the transfer of these shares of Deer Pharmaceuticals at a listed price of not less than RMB 39,747,229
.
58
.
The board of directors of Kang Enbei approved the transfer of these shares of Deer Pharmaceuticals at a listed price of not less than RMB 39,747,229
.
The 25% equity of Dear Pharmaceuticals was acquired by Jinhua Kangenbei in April 2015 with a capital investment of RMB 27.
5 million.
However, in view of the fact that Dear Pharmaceuticals has not launched any new competitive products in recent years, the competitiveness of existing products has gradually increased.
Decrease, its main product, Xie Duan Zhuanggu Capsule, has not been included in the medical insurance, and there are greater uncertainties in the future business development.
Jinhua Kang Enbei intends to dispose of the equity held by Deer Pharmaceuticals
.
At present, the major shareholder of Dear Pharmaceuticals is Hainan Asia Pharmaceutical Co.
, Ltd.
, accounting for 52.
73%; other shareholders include: Zhang Yonggao, accounting for 16.
34%, and the other 6 natural-person shareholders accounting for 5.
93%
.
5 million.
However, in view of the fact that Dear Pharmaceuticals has not launched any new competitive products in recent years, the competitiveness of existing products has gradually increased.
Decrease, its main product, Xie Duan Zhuanggu Capsule, has not been included in the medical insurance, and there are greater uncertainties in the future business development.
Jinhua Kang Enbei intends to dispose of the equity held by Deer Pharmaceuticals
.
At present, the major shareholder of Dear Pharmaceuticals is Hainan Asia Pharmaceutical Co.
, Ltd.
, accounting for 52.
73%; other shareholders include: Zhang Yonggao, accounting for 16.
34%, and the other 6 natural-person shareholders accounting for 5.
93%
.
Speed up the mobilization of funds, Conba "continuous action"
Recently, Conba has been busy selling equity and assets.
In order to release equity pledges, repay debts, and develop products, Conba has transferred the equity of 4 holding companies in the past six months
.
In order to release equity pledges, repay debts, and develop products, Conba has transferred the equity of 4 holding companies in the past six months
.
On June 12, Zhejiang Conba Pharmaceutical Co.
, Ltd.
intends to transfer the 30% equity of Lanxi City Lanxin Small Loan Co.
, Ltd.
through the Zhejiang Equity Exchange.
The transfer will eventually cost 53.
37 million yuan.
The transfer was completed, and the industrial and commercial change registration and filing procedures were completed on October 28
.
, Ltd.
intends to transfer the 30% equity of Lanxi City Lanxin Small Loan Co.
, Ltd.
through the Zhejiang Equity Exchange.
The transfer will eventually cost 53.
37 million yuan.
The transfer was completed, and the industrial and commercial change registration and filing procedures were completed on October 28
.
On August 13, Zhejiang Conba Pharmaceutical Co.
, Ltd.
issued an announcement stating that the board of directors agreed that the company would transfer 100% equity of Guizhou Beite Pharmaceutical Co.
, Ltd.
through public listing in Zhejiang Equity Exchange; on November 6 it issued a supplementary announcement saying that it was the first time At the expiration of the listing period, no interested transferee of equity has been solicited
.
, Ltd.
issued an announcement stating that the board of directors agreed that the company would transfer 100% equity of Guizhou Beite Pharmaceutical Co.
, Ltd.
through public listing in Zhejiang Equity Exchange; on November 6 it issued a supplementary announcement saying that it was the first time At the expiration of the listing period, no interested transferee of equity has been solicited
.
On September 23, Zhejiang Conba Pharmaceutical Co.
, Ltd.
intends to transfer its 42% equity in Jiangxi Zhenshiming Pharmaceutical Co.
, Ltd.
through public listing in Zhejiang Property Rights Exchange, at a listed reserve price of not less than 1,680,000,000 yuan.
No new progress has been announced yet
.
, Ltd.
intends to transfer its 42% equity in Jiangxi Zhenshiming Pharmaceutical Co.
, Ltd.
through public listing in Zhejiang Property Rights Exchange, at a listed reserve price of not less than 1,680,000,000 yuan.
No new progress has been announced yet
.
In addition to the transfer of equity, Conba has also recently released a number of pledges and returned the funds raised.
The company's core managers and shareholders have also announced the shareholding increase plan.
It seems that the move to revitalize the funds has achieved obvious results
.
The company's core managers and shareholders have also announced the shareholding increase plan.
It seems that the move to revitalize the funds has achieved obvious results
.
Many pharmaceutical companies "sell and sell"
Many pharmaceutical companies "sell and sell" At the end of the year, many pharmaceutical companies sold their assets and transferred shares one after another in order to make their annual reports more "beautiful"
.
.
On the evening of November 19, Renfu Medicine issued an announcement stating that it had signed a "Share Transfer Agreement" with Anda North America on November 19, 2021, and planned to transfer approximately 2.
52% of the company's shares of Huatai Insurance to it at a transfer price of RMB About 1.
026 billion yuan
.
Medicine Medicine Medicine52% of the company's shares of Huatai Insurance to it at a transfer price of RMB About 1.
026 billion yuan
.
On the evening of November 15, Laimei Pharmaceutical announced that Chengdu Yaoyun Pharmaceutical Technology Co.
, Ltd.
planned to increase the capital of Chengdu Jinxing Health Pharmaceutical Co.
, Ltd.
, a subsidiary of the listed company, by 113 million yuan
.
After the transaction is completed, Yaoyun Pharmaceutical will hold 61% of the equity of Jinxing Pharmaceutical
.
Upon completion of the transaction, Laimei Pharmaceutical's shareholding in Jinxing Pharmaceutical will drop from 90% to 35.
1%, and Jinxing Pharmaceutical will no longer be included in Laimei Pharmaceutical's consolidated statements
.
, Ltd.
planned to increase the capital of Chengdu Jinxing Health Pharmaceutical Co.
, Ltd.
, a subsidiary of the listed company, by 113 million yuan
.
After the transaction is completed, Yaoyun Pharmaceutical will hold 61% of the equity of Jinxing Pharmaceutical
.
Upon completion of the transaction, Laimei Pharmaceutical's shareholding in Jinxing Pharmaceutical will drop from 90% to 35.
1%, and Jinxing Pharmaceutical will no longer be included in Laimei Pharmaceutical's consolidated statements
.
On the evening of November 11, Dongyang Sunshine issued an announcement stating that the company intends to transfer the company’s total 452 million shares of Dongyang Sunshine to Guangdong Dongyang Sunshine Pharmaceutical Co.
, Ltd.
and its wholly-owned subsidiary, Hong Kong Dongyang Sunshine Sales Co.
, Ltd.
, accounting for approximately Dongyang Sunshine.
51.
41% of Sunshine Pharmaceutical’s total equity, with a transaction price of 3.
723 billion yuan
.
, Ltd.
and its wholly-owned subsidiary, Hong Kong Dongyang Sunshine Sales Co.
, Ltd.
, accounting for approximately Dongyang Sunshine.
51.
41% of Sunshine Pharmaceutical’s total equity, with a transaction price of 3.
723 billion yuan
.
On November 4, Jinghua Pharmaceutical issued an announcement stating that it had recently completed the sale of equity in its subsidiary Wannianchang Pharmaceutical
.
Upon notification from Nantong Public Resources Trading Center, the transferee of the equity is Jiangsu Qichen New Materials Co.
, Ltd.
, with a transaction amount of RMB 69,398,739.
00
.
.
Upon notification from Nantong Public Resources Trading Center, the transferee of the equity is Jiangsu Qichen New Materials Co.
, Ltd.
, with a transaction amount of RMB 69,398,739.
00
.
The sale of non-core business, the transfer of unprofitable subsidiaries for corporate sustainable development is favorable; revitalize the capital, to resolve the current difficulties, focus on core product R & D investment, the national pharmaceutical industry wants to focus, healthy development objectives
.
Enterprise business enterprise health health health .
